Allied Market Research

Recombinant Chinese Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market 2023


Portland, OR -- (SBWIRE) -- 09/19/2017 -- Hepatitis B is a viral infection caused due to transmission of the virus through contact with the blood or other body fluids of an infected person. It is considered as a serious occupational hazard for healthcare professionals, which affects the liver, causing acute and chronic diseases. Hence, Chinese hamster ovary cell (CHO) hepatitis B vaccine is considered to be the safe and effective method to prevent the hepatitis B infection. The major factor that fuels the growth of the market are increase in prevalence of hepatitis B infection worldwide. For example, approximately 887,000 deaths due to hepatitis B infection were recorded in 2015 across the globe. However, inherent disadvantages of using recombinant Chinese hamster ovary cell (CHO) to design hepatitis B vaccines restrains the growth of the market. Conversely, increase in government focus to promote (CHO) hepatitis B vaccination for adults and extensive research carried out for the same are expected to offer lucrative opportunities for the market.

Access the full summarty at:

Get PDF Brochure of this report:

The key players profiled in this report are Merck & Co., Inc., GlaxoSmithKline Plc, Pfizer Inc., Sanofi Pasteur, CSL Limited, Emergent Biosolutions, Serum Institute of India, and Johnson & Johnson.

Key Benefits

-The study provides an in-depth analysis of the global recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccine market with current trends and future estimations to elucidate the imminent investment pockets.

-It presents a quantitative analysis from 2016 to 2023 to enable the stakeholders to capitalize on prevailing market opportunities.

-Extensive analysis of the market by type assists to understand the various forms of recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccines available.

-Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.

Early buyers will receive 20% customization on this report